LeMaitre Vascular (LMAT) Form 4: Kamke Records Dividend Equivalent Rights

Rhea-AI Filing Summary

LeMaitre Vascular insider report: This Form 4, filed for Trent G. Kamke (Senior V.P., Operations), discloses accrual and acquisition of dividend equivalent rights tied to restricted stock unit (RSU) and performance share unit (PSU) awards that vest proportionately. Transactions are dated 09/04/2025. The report lists multiple accruals that convert economically to common shares, with individual tranche amounts shown (examples: 0.3386, 0.6173, 1.2562, 1.6108, 1.9307, 1.9194). No cash consideration is reported and ownership form is direct. The filing documents routine compensation-related accruals rather than open-market purchases or sales.

Insights

Securities Analyst

TL;DR: Routine compensation accruals; not a material change to ownership or corporate control.

The Form 4 reports dividend equivalent rights credited to RSU and PSU awards for Trent Kamke on 09/04/2025. Each credit is the economic equivalent of common stock and vests proportionately with the underlying awards. There is no cash price reported and the quantities are fractional per award tranche, indicating these are bookkeeping entries recognizing accrued dividends rather than purchases or dispositions that would change voting power materially. Impact on share count and dilution is negligible at the single- and low-double-digit fractional-share level reported.

Corporate Governance Expert

TL;DR: Administrative disclosure of compensation-related rights; standard governance transparency.

The filing fulfills Section 16 reporting for an officer receiving dividend equivalent credits tied to long-term incentive awards (RSUs and PSUs). The explanations tie each credited tranche to prior grants dated 2020–2024. This disclosure aligns with required transparency around executive compensation accruals and does not indicate any alteration to incentive terms or issuance of new awards. For governance reviewers, the form confirms vesting-linked accruals and direct beneficial ownership reporting consistent with company equity plans.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kamke Trent G

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR , INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior V. P., Operations

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.3386		(1)	(1)	Common Stock	0.3386	$0	12.7592	D
Dividend Equivalent Rights	(2)	09/04/2025		A		0.6173		(2)	(2)	Common Stock	0.6173	$0	13.6149	D
Dividend Equivalent Rights	(3)	09/04/2025		A		1.2562		(3)	(3)	Common Stock	1.2562	$0	15.3084	D
Dividend Equivalent Rights	(4)	09/04/2025		A		1.2562		(4)	(4)	Common Stock	1.2562	$0	15.3	D
Dividend Equivalent Rights	(5)	09/04/2025		A		1.6108		(5)	(5)	Common Stock	1.6108	$0	11.4481	D
Dividend Equivalent Rights	(6)	09/04/2025		A		1.9307		(6)	(6)	Common Stock	1.9307	$0	12.5182	D
Dividend Equivalent Rights	(7)	09/04/2025		A		1.9194		(7)	(7)	Common Stock	1.9194	$0	6.4209	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/2/2020 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

7. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Trent G. Kamke report on the Form 4 for LMAT?

The filing reports accrual and acquisition of dividend equivalent rights tied to RSU and PSU awards that vest proportionately, dated 09/04/2025.

Do the reported transactions involve cash purchases or sales for LMAT?

No. The entries reflect dividend equivalent rights credited to awards with a reported price of $0, not open-market purchases or sales.

Are the dividend equivalent rights linked to specific award grant dates?

Yes. The explanations cite awards granted on 12/2/2020, 12/11/2021, 12/12/2022, 12/8/2023, and 12/6/2024.

Does this Form 4 indicate a material change in ownership for LMAT?

No. The report shows fractional-share equivalent credits and routine vesting-related accruals; it does not indicate a material change in control or large ownership shift.

What ownership form is reported for these accruals?

The filing reports the ownership form as Direct (D) for the dividend equivalent rights.